Regeneus CEO Leo Lee with Proactive at the ASX Small and Mid-Cap Conference 2020

Regeneus CEO Leo Lee speaks to Proactive Investors' Andrew Scott while at the virtual ASX Small and Mid-Cap Conference 2020. During the interview, Leo talks about how Regeneus is working towards its mission to improve the quality of life for patients suffering from pain through their regenerative medicine products Progenza and Sygenus, the recent deal with Japanese manufacturing giant Kyocera Corporation, the experience of Regeneus' Board, and the current opportunity for investors.

Watch Leo's full interview with Proactive Investors here.

Mesenchymal Stem Cells: The Next Generation of Pain Treatments

Regeneus CEO Leo Lee is featured in the October 2020 edition of the European Pharmaceutical Review, writing on the field of regenerative medicine and its potential to dramatically transform the way that pain is treated.

Read Leo's full article in the European Pharmaceutical Review October 2020 digital edition here.

Regeneus featured in Morgans ‘Under The Microscope’ podcast

Morgans analyst Iain Wilkie sat down with Regeneus CEO Leo Lee to talk about the company's recent collaboration and licensing deal for Progenza OA for knee osteoarthritis in Japan and what it means for the company.

Listen to the podcast here.

Dr Boreham's Crucible: Regeneus is now riding the stem cell rollercoaster upwards

Business and life sciences writer Tim Boreham recently featured Regeneus in his regular biotech stocks column, Dr Boreham’s Crucible.

The column, published on Stockhead, reported that Regeneus' deal with Kyocera was important as it provided a clear commercialisation pathway for the lead stem cell platform technology Progenza.

Read the full article via Stockhead here.

Aussie stem cell company Regeneus out-licenses Progenza to Kyocera for Japan market

Biotechnology and biopharmaceutical industry publication, BioWorld, also covered the news on Regeneus out-licensing its lead mesenchymal stem cell (MSC) and Secretome therapy, Progenza, to Japan’s Kyocera Corporation for osteoarthritis of the knee for the Japan market, The report noted Kyocera has a strong presence among, and relationships with, physicians who treat osteoarthritis, and that this would help Progenza in the long term.

Read the full article here.

Regeneus, Kyocera ink $19M deal for knee osteoarthritis treatment

Bio and Health Sciences publication BioSpectrum covered Regeneus' deal with Kyocera for Progenza OA in Japan in their Asia Edition.

Read the full article in BioSpectrum Asia here.

Regeneus (ASX:RGS) Announces Collaboration With Kyocera

Regeneus CEO Leo Lee caught up with Finance News Network to talk about the company's collaboration with Japan's Kyocera Corporation to licence, manufacture and commercialise its stem cell therapy treatment Progenza.

Watch Leo's interview via The West Australian here

Regeneus CEO Leo Lee interviewed on ausbiz

Regeneus CEO Leo Lee was interviewed by Australian business, markets, startups news outlet, ausbiz, on Tuesday 11 August following the announcement that Regeneus had signed a new collaboration and licensing agreement with Kyocera for Progenza OA in Japan. In the interview, Leo noted the upfront and milestones payments were worth $27M, and that Regeneus would also receive royalties on product sales.

In the interview, Leo also noted that there were more than 25M potential patients with osteoarthritis in Japan, and that the number of people receiving treatment is rising each year.

Watch Leo's interview here.

Regeneus and Kyocera ink lucrative deal to commercialise Progenza in $3.5 billion dollar market

Financial news outlet finfeed featured Regeneus' Kyocera deal on the day of the announcement, offering in depth analysis of the company, the progress made so far in addressing the global pain market through its differentiated technologies, and the upcoming milestones investors can look forward to.

Read the full article via finfeed here.

Regeneus receives milestone payment from Kyocera

Australian biotechnology and life sciences online news source, BiotechDaily, reported that Regeneus received a non-refundable milestone payment of approximately $1.6 million (100 million Japanese Yen) from Kyocera Corporation as set out in the non-binding Memorandum of Understanding (MOU) signed on 2 March 2020.

Read the full article here.

Regeneus inks agreement with high profile Japanese life sciences group

Online investment publication Finfeed reported that Regeneus signed a non-binding memorandum of understanding (MOU) with Kyocera Corporation (Kyocera, TYO:6971), a diversified Japanese-based manufacturer with a strong position in the life sciences industry.

Read the full article here.

Regeneus (ASX:RGS) signs MOU with Kyocera for Progenza

The Market Herald - a leading source of authoritative breaking stock market news for self-directed investors - published an article reporting on Regeneus signing a non-binding memorandum of understanding with Kyocera Corporation.

Read the full article here.

ASX:RGS - Regeneus AGC Agreement termination paves way for commercial partner

Regeneus’ CEO Leo Lee spoke with Boardroom Media to discuss the recent termination of our AGC agreement and what it means for potential partners for our lead candidate, Progenza OA in Japan.

Listen to the full interview via Boardroom Media